AdvocacyRSSToday
A caregiver shares his personal story about losing his wife Mary Ann to ALS (a disease that affects nerve cells controlling muscles) after 34 years of marriage. The article describes their medical journey, which began with neurologic symptoms in 2011 and initially included a misdiagnosis of Parkinson's disease before she was correctly diagnosed with ALS.
WHY IT MATTERSThis personal account highlights the diagnostic challenges ALS patients face—Mary Ann was initially misdiagnosed with Parkinson's disease—which is important for newly symptomatic patients to understand they may need multiple evaluations before getting an accurate diagnosis.
ResearchRSSYesterday
Scientists discovered that people with ALS who carry a specific gene variant called APOE4 (known to increase Alzheimer's risk) are more likely to have toxic protein clumps spread to more areas of their brain. This suggests the same gene may affect how disease progresses differently in ALS patients. The finding could help doctors better understand why ALS affects people differently.
WHY IT MATTERSIf you have ALS and carry the APOE4 variant, this research suggests you may experience different patterns of disease progression, which could eventually help doctors predict outcomes and tailor treatment approaches for individual patients.
NewsRSS2 days ago
This article shares a personal story from a caregiver whose husband Todd has ALS (a disease that causes paralysis and muscle weakness). While showering and caring for her husband, she discovered a song called 'Mercy Now' that resonated with the challenges the ALS community faces. The piece highlights the emotional and physical toll of living with ALS on both patients and their families.
WHY IT MATTERSCaregivers of ALS patients often experience isolation and emotional burden—this story validates those experiences and may help others feel less alone in their caregiving journey.
GrantRSS2 days ago
A company called Outsee won a major award worth about $10 million to use artificial intelligence and patient genetic information to find new ways to treat ALS, a disease that affects nerve cells in the brain and spinal cord. This award is part of a larger global competition called the Longitude Prize on ALS that aims to speed up the discovery of new treatments for this serious condition.
WHY IT MATTERSThis funding could accelerate the discovery of new ALS treatment targets by combining AI technology with real patient genetic data, potentially leading to novel therapies for a disease with limited treatment options.
ResearchRSS3 days ago
A new study found that statin drugs, which lower cholesterol, do not slow down ALS or change how long people with ALS live. This means doctors should prescribe statins to ALS patients based on their cholesterol levels, not because of their ALS diagnosis.
WHY IT MATTERSIf you have ALS and high cholesterol, you can now feel confident that taking statins for your heart health won't interfere with your ALS treatment or make your disease worse.
ResearchRSS4 days ago
Scientists found that some people with ALS get worse faster than others because of differences in how their immune cells cause inflammation. The study shows that the amount of inflammation in the spinal cord isn't the main factor — instead, it's the type of immune activity that matters. This discovery could lead to new treatments that slow down ALS by targeting specific inflammatory markers.
WHY IT MATTERSIf doctors can identify which inflammatory markers predict faster progression, they may be able to personalize treatment plans and potentially slow disease advancement for individual ALS patients.
Clinical trialRSS5 days ago
A company called Neurizon Therapeutics has been approved to test a new liquid version of a drug called NUZ-001 in Australia. This drug is being developed to treat ALS, a disease that affects nerve cells and causes muscle weakness. The company is testing this liquid form in healthy volunteers, while a tablet version of the same drug is already being tested in a larger trial in the United States.
WHY IT MATTERSIf the liquid formulation proves safe and effective, it could offer ALS patients an easier-to-take alternative to a tablet, which may improve medication adherence for people with swallowing difficulties—a common symptom of ALS.